Narcolepsy

Sleep-related eating disorder after dose escalation of sodium oxybate in narcolepsy type 1.

Sodium oxybate (SO) is an effective therapy for narcolepsy type 1 (NT1) but has been infrequently linked to complex sleep-related behaviors. We describe a case of NT1 who developed sleep-related eating disorder (SRED) after progressive gradual titration of SO. A 15-year-old female was diagnosed with…

Sodium-relevant comorbidity risk factors are highly prevalent in individuals with narcolepsy or idiopathic hypersomnia.

Individuals with narcolepsy or idiopathic hypersomnia (IH) present with a high comorbidity burden that may confer elevated risk for negative clinical outcomes associated with excess sodium intake. This study characterized the prevalence and profiles of sodium-relevant comorbidity risk factors among…

Assessment of readiness in the diagnosis and management of central disorders of hypersomnolence: A survey of sleep medicine program directors and fellowship graduates.

Central disorders of hypersomnolence (CDH), including narcolepsy, idiopathic hypersomnia, and recurrent hypersomnia, are rare conditions that pose challenges in sleep medicine fellowship training. Limited exposure to these disorders, variability in training experiences, and growing complexity of dia…

The Italian registry for narcolepsy and central disorders of hypersomnolence (ReN&IS): Baseline clinical and diagnostic findings.

Central disorders of hypersomnolence, a wide and heterogeneous group of neurological disorders including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), are chronic, rare, under-recognized, and disabling conditions characterized by excessive daytime sleepiness (EDS…

Stimulant Use Disorder.

Primary care providers (PCPs) are often tasked to care for those with stimulant use, both prescribed and illicit. The increasing use of stimulants across all age graphics has become more prevalent over the last several decades. The challenges of managing use and misuse are becoming more common for t…

Novel Compounds as Orexin 2 Receptor Agonists for Treating Narcolepsy.

Provided herein are novel compounds as orexin 2 receptor agonists, pharmaceutical compositions, use of such compounds in treating narcolepsy, and processes for preparing such compounds.

First-of-its-kind narcolepsy drug opens door to new therapies for the brain.

Daily briefing: Narcolepsy drug could kick off an Ozempic-style moment for the brain.